医学界肿瘤频道|中国原创惊艳亮相ASCO：36% PSC、22%脑转移，疾病控制仍高达93.4%( 二 )

参考文献
[1]Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+). First Author: Shun Lu, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China,2020ASCO.
[2]https://www.chemicalbook.com/ChemicalProductProperty_CN_CB72550731.htm [3]Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492 PMID:30207593. [4]Ferlay J, et al (2018). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today. Accessed 20 March 2020. [5]Zhongguo Fei Ai Za Zhi.Intraoperative Molecular Imaging of Lung Adenocarcinoma Can Identify Residual Tumor Cells at the Surgical Margins 2015 Dec20; 18(12):745–751. doi: 10.3779/j.issn.1009-3419. [6]https://www.novartis.com/news/media-releases/novartis-announces-met-inhibitor-capmatinib-inc280-first-potential-treatment-metex14-mutated-advanced-non-small-cell-lung-cancer-granted-priority-fda-review [7]TEPMETKO (Tepotinib) Approved in Japan for Advanced NSCLC with METex14 Skipping Alterations [8]https://www.merckgroup.com/en/news/tepotinib-25-03-2020.html